메뉴 건너뛰기




Volumn 455, Issue 3-4, 2014, Pages 269-276

Synergistic cytotoxicity of afatinib and cetuximab against EGFR T790M involves Rab11-dependent EGFR recycling

Author keywords

Cytotoxicity; EGFR; EGFR TKI

Indexed keywords

AFATINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; RAB11 PROTEIN; RITUXIMAB; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; ONCOPROTEIN; QUINAZOLINE DERIVATIVE; RAB PROTEIN;

EID: 84914176984     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.11.003     Document Type: Article
Times cited : (28)

References (24)
  • 1
    • 33847323129 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations in lung cancer
    • S.V. Sharma, D.W. Bell, and J. Settleman Epidermal growth factor receptor mutations in lung cancer Nat. Rev. Cancer 7 2007 169 181
    • (2007) Nat. Rev. Cancer , vol.7 , pp. 169-181
    • Sharma, S.V.1    Bell, D.W.2    Settleman, J.3
  • 2
    • 35548962203 scopus 로고    scopus 로고
    • Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
    • T. Mitsudomi, and Y. Yatabe Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci. 98 2007 1817 1824
    • (2007) Cancer Sci. , vol.98 , pp. 1817-1824
    • Mitsudomi, T.1    Yatabe, Y.2
  • 3
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
    • (2004) N. Engl. J. Med. , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 4
    • 4444344330 scopus 로고    scopus 로고
    • EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    • W. Pao, V. Miller, and M. Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. U.S.A. 101 2004 13306 13311
    • (2004) Proc. Natl. Acad. Sci. U.S.A. , vol.101 , pp. 13306-13311
    • Pao, W.1    Miller, V.2    Zakowski, M.3
  • 5
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N. Engl. J. Med. 361 2009 947 957
    • (2009) N. Engl. J. Med. , vol.361 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 6
    • 77953930730 scopus 로고    scopus 로고
    • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    • M. Maemondo, A. Inoue, and K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N. Engl. J. Med. 362 2010 2380 2388
    • (2010) N. Engl. J. Med. , vol.362 , pp. 2380-2388
    • Maemondo, M.1    Inoue, A.2    Kobayashi, K.3
  • 7
    • 35648949422 scopus 로고    scopus 로고
    • BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
    • discussion 1680
    • D.B. Costa, B. Halmos, and A. Kumar BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations PLoS Med. 4 2007 1669 1679 discussion 1680
    • (2007) PLoS Med. , vol.4 , pp. 1669-1679
    • Costa, D.B.1    Halmos, B.2    Kumar, A.3
  • 8
    • 84875721996 scopus 로고    scopus 로고
    • BIM, PUMA, and the achilles' heel of oncogene addiction
    • A. Roulston, W.J. Muller, and G.C. Shore BIM, PUMA, and the achilles' heel of oncogene addiction Sci. Signal. 6 2013 pe12
    • (2013) Sci. Signal. , vol.6 , pp. 12
    • Roulston, A.1    Muller, W.J.2    Shore, G.C.3
  • 9
    • 13844317894 scopus 로고    scopus 로고
    • EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    • S. Kobayashi, T.J. Boggon, and T. Dayaram EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 352 2005 786 792
    • (2005) N. Engl. J. Med. , vol.352 , pp. 786-792
    • Kobayashi, S.1    Boggon, T.J.2    Dayaram, T.3
  • 10
    • 18244371651 scopus 로고    scopus 로고
    • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    • W. Pao, V.A. Miller, and K.A. Politi Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2 2005 e73
    • (2005) PLoS Med. , vol.2 , pp. 73
    • Pao, W.1    Miller, V.A.2    Politi, K.A.3
  • 11
    • 49149118719 scopus 로고    scopus 로고
    • BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    • D. Li, L. Ambrogio, and T. Shimamura BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27 2008 4702 4711
    • (2008) Oncogene , vol.27 , pp. 4702-4711
    • Li, D.1    Ambrogio, L.2    Shimamura, T.3
  • 12
    • 84862785051 scopus 로고    scopus 로고
    • Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
    • V.A. Miller, V. Hirsh, and J. Cadranel Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Lancet Oncol. 13 2012 528 538
    • (2012) Lancet Oncol. , vol.13 , pp. 528-538
    • Miller, V.A.1    Hirsh, V.2    Cadranel, J.3
  • 13
    • 84862819699 scopus 로고    scopus 로고
    • Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
    • J.C. Yang, J.Y. Shih, and W.C. Su Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial Lancet Oncol. 13 2012 539 548
    • (2012) Lancet Oncol. , vol.13 , pp. 539-548
    • Yang, J.C.1    Shih, J.Y.2    Su, W.C.3
  • 14
    • 16244400108 scopus 로고    scopus 로고
    • Cetuximab: An epidermal growth factor receptor chemeric human-murine monoclonal antibody
    • J. Harding, and B. Burtness Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody Drugs Today (Barc.) 41 2005 107 127
    • (2005) Drugs Today (Barc.) , vol.41 , pp. 107-127
    • Harding, J.1    Burtness, B.2
  • 15
    • 84890862301 scopus 로고    scopus 로고
    • EGF receptor trafficking: Consequences for signaling and cancer
    • A. Tomas, C.E. Futter, and E.R. Eden EGF receptor trafficking: consequences for signaling and cancer Trends Cell Biol. 24 2014 26 34
    • (2014) Trends Cell Biol. , vol.24 , pp. 26-34
    • Tomas, A.1    Futter, C.E.2    Eden, E.R.3
  • 16
    • 63649086486 scopus 로고    scopus 로고
    • The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins
    • C. Raiborg, and H. Stenmark The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins Nature 458 2009 445 452
    • (2009) Nature , vol.458 , pp. 445-452
    • Raiborg, C.1    Stenmark, H.2
  • 17
    • 84906911022 scopus 로고    scopus 로고
    • Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations
    • Y.Y. Janjigian, E.F. Smit, and H.J. Groen Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations Cancer Discov. 4 2014 1036 1045
    • (2014) Cancer Discov. , vol.4 , pp. 1036-1045
    • Janjigian, Y.Y.1    Smit, E.F.2    Groen, H.J.3
  • 18
    • 70349684791 scopus 로고    scopus 로고
    • Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer
    • L. Regales, Y. Gong, and R. Shen Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer J. Clin. Invest. 119 2009 3000 3010
    • (2009) J. Clin. Invest. , vol.119 , pp. 3000-3010
    • Regales, L.1    Gong, Y.2    Shen, R.3
  • 19
    • 69249106881 scopus 로고    scopus 로고
    • Pathways and mechanisms of endocytic recycling
    • B.D. Grant, and J.G. Donaldson Pathways and mechanisms of endocytic recycling Nat. Rev. Mol. Cell Biol. 10 2009 597 608
    • (2009) Nat. Rev. Mol. Cell Biol. , vol.10 , pp. 597-608
    • Grant, B.D.1    Donaldson, J.G.2
  • 20
    • 10444267243 scopus 로고    scopus 로고
    • Cetuximab (Erbitux) - An emerging targeted therapy for epidermal growth factor receptor-expressing tumours
    • M. Ng, and D. Cunningham Cetuximab (Erbitux) - an emerging targeted therapy for epidermal growth factor receptor-expressing tumours Int. J. Clin. Pract. 58 2004 970 976
    • (2004) Int. J. Clin. Pract. , vol.58 , pp. 970-976
    • Ng, M.1    Cunningham, D.2
  • 21
    • 35648953299 scopus 로고    scopus 로고
    • Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics
    • discussion 1690
    • M.S. Cragg, J. Kuroda, and H. Puthalakath Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics PLoS Med. 4 2007 1681 1689 discussion 1690
    • (2007) PLoS Med. , vol.4 , pp. 1681-1689
    • Cragg, M.S.1    Kuroda, J.2    Puthalakath, H.3
  • 22
    • 33644865025 scopus 로고    scopus 로고
    • Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function
    • X.J. Qi, G.M. Wildey, and P.H. Howe Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function J. Biol. Chem. 281 2006 813 823
    • (2006) J. Biol. Chem. , vol.281 , pp. 813-823
    • Qi, X.J.1    Wildey, G.M.2    Howe, P.H.3
  • 23
    • 75749096347 scopus 로고    scopus 로고
    • The endocytic matrix
    • G. Scita, and P.P. Di Fiore The endocytic matrix Nature 463 2010 464 473
    • (2010) Nature , vol.463 , pp. 464-473
    • Scita, G.1    Di Fiore, P.P.2
  • 24
    • 71949085528 scopus 로고    scopus 로고
    • Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src
    • B.M. Chung, S.M. Raja, and R.J. Clubb Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src BMC Cell Biol. 10 2009 84
    • (2009) BMC Cell Biol. , vol.10 , pp. 84
    • Chung, B.M.1    Raja, S.M.2    Clubb, R.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.